Investigators Discuss Available Research Guiding the Care of Patients with Non-Hodgkin Lymphoma

Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

LEARNING OBJECTIVES

• Evaluate published research establishing the efficacy and safety of Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and potential clinical role of various BTK inhibitor-based strategies for patients newly diagnosed with the disease.
• Identify patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for whom the use of CD79b-targeted therapy as a component of first-line treatment would be appropriate.
• Develop an understanding of available clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and employ this information as part of patient education discussions.
• Appraise the available research findings with and current clinical role of CD19-targeted antibody-drug conjugates in treatment for patients with R/R DLBCL.
• Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, FL and MCL, and counsel appropriately selected patients regarding the potential benefits of this therapeutic strategy.
• Evaluate the available trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and DLBCL, and determine the role of these agents in clinical management.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/NHL/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Joshua Brody, MD
Director, Lymphoma Immunotherapy Program
The Tisch Cancer Institute at Mount Sinai
Faculty Member, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
New York, New York

No relevant financial relationships to disclose.

Christopher Flowers, MD, MS
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.

Ann LaCasce, MD, MMSc
Associate Professor, Hematology and Medical Oncology
Program Director, Dana-Farber/MGB Fellowship in Hematology/Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Advisory Committees: Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Pierre Fabre.

Tycel Phillips, MD, FASCO
Associate Professor, Division of Lymphoma
Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
Duarte, California

Advisory Committees: AbbVie Inc, Genentech, a member of the Roche Group,Genmab US Inc, Merck; Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Xencor; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Sobi; Nonrelevant Financial Relationships: Leukemia & Lymphoma Society (LLS) Scholar in Clinical Research.

MODERATOR
Jeremy S Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Allogene Therapeutics, Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, and Incyte Corporation.

Release date: June 2025
Expiration date: June 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Flowers

Abramson JS et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study. Blood 2023;141(14):1675-84. Abstract

Alu A et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies. J Hematol Oncol 2022;15(1):138. Abstract

Bartlett NL et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol 2025;43(9):1061-72. Abstract

Caimi PF et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 2024;109(4):1184-93. Abstract

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica 2024109(2):553-66. Abstract

Kamdar M et al. Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. ASCO 2024;Abstract 7013.

Li X et al. Comprehensive characterization and validation of the tumor microenvironment in patients with relapsed/refractory large B-cell lymphoma identifies subgroups with greatest benefit from CD19 CAR T-cell therapy. ASH 2024;Abstract 643.

Mouhssine S et al. Targeting BTK in B cell malignancies: From mode of action to resistance mechanisms. Int J Mol Sci 2024;25(6):3234. Abstract

Palmer et al. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med 2023;389(8):764-6. Abstract

Salles G et al. Five-year analysis of the POLARIX Study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. ASH 2024;Abstract 469.

Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract

Sehn LH et al. ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL). ASCO 2021;Abstract TPS7572.

Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract

Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023;389(2):148-57. Abstract

 

Dr Phillips

Dreyling M et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 2024;403(10441):2293-306. Abstract

Kumar A et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood 2025;145(5):497-507. Abstract

Lewis DJ et al. Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: Results from the international randomised controlled trial, Enrich. ASH 2024;Abstract 235.

Mant S et al. A prospective analysis of newly diagnosed mantle cell lymphoma: Predictors and survival of indolent disease. EHA 2024;Abstract S230.

Wang M et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024;Abstract LB3439.

Wang M et al. Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2. ASCO 2022;Abstract 7518.

 

Dr LaCasce

Alderuccio JP et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12(1):e23-34. Abstract

Isshiki Y et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell 2025;43(1):49-68.e9. Abstract

Leonard JP et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37:1188-99. Abstract

Morchhauser F et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21(11):1433-42. Abstract

Proudman DG et al. Tazemetostat in relapsed/refractory follicular lymphoma: A propensity score-matched analysis of E7438-G000-101 trial outcomes. Oncotarget 2022:13:677-83. Abstract

Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.

Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2023;41(33):5107-17. Abstract

 

Dr Brody

Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. ASCO 2025;Abstract 7015.

Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial. Lancet 2024;404(10466):1940-54. Abstract

Brody JD et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: Results from the EPCORE NHL-2 trial. Blood 2025;145(15):1621-31. Abstract

Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract

Dickinson MJ et al. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH 2024;Abstract 865.

Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract

Gaballah S et al. Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: High complete responses seen in CAR-T-naive and CAR-T-exposed patients. ASH 2024;Abstract 868.

Leslie LA et al. Epcoritamab with rituximab + lenalidomide (R²) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7. ASCO 2024;Abstract 7014.

Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract

Olszewski AJ et al. Mosunetuzumab with response-driven lenalidomide augmentation as first-line therapy for symptomatic follicular or marginal zone lymphoma: Interim analysis of a multi-center phase 2 study. ASH 2024;Abstract 1644.

Phillips TJ et al. Glofitamab in relapsed/refractory mantle cell lymphoma: Results from a phase I/II study. J Clin Oncol 2025;43(3):318-28. Abstract

Sehn LH et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood 2025;145(7):708-19. Abstract

Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract

 

Dr Abramson

Abramson JS et al. Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL). ASH 2024;Abstract 3125.

Abramson JS et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by ASCT as second-line treatment in patients with R/R large B-cell lymphoma: 3-year follow-up of TRANSFORM. EHA 2024;Abstract S272.

Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629-39. Abstract

Jaeger U et al. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2022;6(16):4816-20. Abstract

Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract

Nastoupil L et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Transcend FL 2-year follow-up. ASH 2024;Abstract 4387.

Neelapu SS et al.  5-year follow-up analysis from ZUMA-5: A phase 2 trial of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2024;Abstract 864.

Neelapu SS et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141(19):2307-15. Abstract

Thieblemont C et al. Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 ELARA 4-year update. ASH 2024;Abstract 3034.

Wang M et al. Lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): Results from the final analysis of the MCL cohort of the open-label, phase 1, seamless design, multicenter Transcend NHL 001 (TRANSCEND) study. ASTCT 2025;Abstract S207.

Wang M et al. Five-year outcomes of patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (Brexu-cel) in ZUMA-2 cohorts 1 and 2. ASH 2024;Abstract 4388.

Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023;389(2):148-57. Abstract